EMA Authorised: Tukysa (tucatinib) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA has authorised Tukysa (tucatinib) for use in the European Union for metastatic breast cancer, with Pfizer Europe MA EEIG as the marketing authorization …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tukysa (tucatinib)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Neoplasm Metastasis. MAH: Pfizer Europe MA EEIG. Decision date: 24/11/2025